ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Minnesota's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1992
Meetings & Education
Allied Health Professionals Award
State Society Education Series
MSCO 2020 Fall Conference Highlights
Patient Advocacy Organizations
State & Federal Resources
Financial Advocacy & Patient Assistance
Find A Clinical Trial
National Professional Organizations
Off-Label Use Literature
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma
On November 14, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Brukinsa, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
FDA granted this application priority review and zanubrutinib received orphan product and breakthrough therapy designations for treatment of MCL.
Read FDA announcement